Search results
Showing 1 to 15 of 33 results for alzheimer's disease
Dementia: assessment, management and support for people living with dementia and their carers (NG97)
This guideline covers diagnosing and managing dementia (including Alzheimer’s disease). It aims to improve care by making recommendations on training staff and helping carers to support people living with dementia.
Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (TA217)
Evidence-based recommendations on donepezil (Aricept), galantamine (Reminyl), rivastigmine (Exelon) and memantine (Ebixa) for treating Alzheimer's disease in adults.
In development [GID-TA11220] Expected publication date: 17 July 2024
In development [GID-TA11221] Expected publication date: 11 September 2024
Physical activity: brief advice for adults in primary care (PH44)
This guideline covers providing brief advice on physical activity to adults in primary care. It aims to improve health and wellbeing by raising awareness of the importance of physical activity and encouraging people to increase or maintain their activity level.
This guideline covers mid-life approaches to delay or prevent the onset of dementia, disability and frailty in later life. The guideline aims to increase the amount of time that people can be independent, healthy and active in later life.
NICE's impact on preventing or delaying the onset of dementia
impact of treating Alzheimer 8217;s disease on mortality and institutionalisation and to assess the relationship between...
Gantenerumab for treating early Alzheimer's disease TS ID 10668
Awaiting development [GID-TA11072] Expected publication date: TBC
Hydromethylthionine mesylate for treating Alzheimer's disease TS ID 11890
Awaiting development [GID-TA11379] Expected publication date: TBC
on the effects of treating people with Alzheimer 8217;s disease on both short term and long term outcomes...
Health Technology Assessment Innovation Laboratory (HTA Lab)
NICE's HTA Lab enables us to develop creative solutions to complex problems in health technology assessment.
Melatonin for treating sleep disorders in adults who are blind (ES38)
Summary of the evidence on melatonin for treating sleep disorders in adults who are blind
How NICE recommendations are being used to improve outcomes in priority areas of dementia care